Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 8, 2010International Journal of CancerOpen Access

The BCR/ABL‐inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity

View Full Paper
Ask AI
Bookmark
Share

Authors

JSJulia SalihJHJulia HilpertKarlsruhe University of EducationTPTheresa PlackeBroad Institute

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Salih et al. (2010) studied this question.

synapsesocial.com/papers/6a7d84f8ac8a0219183c8f2fhttps://doi.org/10.1002/ijc.25233
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor.1994 · 1,111 citations
  2. 2Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL2006 · 1,345 citations
  3. 3Cancer immunoediting by GITR (glucocorticoid‐induced TNF‐related protein) ligand in humans: NK cell/tumor cell interactions2007 · 99 citations
  4. 4Glucocorticoid-Induced Tumor Necrosis Factor Receptor–Related Protein Ligand Subverts Immunosurveillance of Acute Myeloid Leukemia in Humans2009 · 74 citations
  5. 5Integrin-mediated Ras–Extracellular Regulated Kinase (ERK) Signaling Regulates Interferon γ Production in Human Natural Killer Cells1998 · 74 citations